Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q4 EPS of $0.48, $0.02 better than the analyst estimate of $0.46. Revenue for the quarter came in at $188.8 million versus the consensus estimate of $187.68 million.

Myriad Genetics, Inc. sees FY2015 EPS of $1.90-$2.00, versus the consensus of $2.11. Myriad Genetics, Inc. sees FY2015 revenue of $800-820 million, versus the consensus of $815.6 million.

For earnings history and earnings-related data on Myriad Genetics, Inc. (MYGN) click here.